First Horizon 13F: Cuts Eli Lilly and (LLY) Stake by $841K
Key Points
- First Horizon's reported value for Eli Lilly is now approximately $14.7 million, making up 1.49% of its total portfolio.
- First Horizon held 12,712 $LLY shares at quarter end, down 5.41% from the prior quarter.
- The stock closed at $1,279.14 on October 26, 2026, and has recently traded around $1,279.16, which is about equal to its event close.
- Analysts have a consensus 'buy' rating on Eli Lilly, with a mean price target of $1,331.55, indicating potential upside from current levels.
Get Eli Lilly and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $LLY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
First Horizon trimmed its stake in Eli Lilly and Company (NYSE: LLY) by 727 shares, bringing its total to 12,712 shares valued at about $14.7 million. This change was disclosed in a filing on October 26, 2026. Prior to this adjustment, First Horizon held 13,439 shares of Eli Lilly.
LLY
Eli Lilly and Company
Where Eli Lilly Fits in First Horizon's Portfolio
First Horizon's stake in Eli Lilly now represents 1.49% of its total reported 13F portfolio, ranking 30th among its 1,514 holdings.
Other Institutional Activity in Eli Lilly
Pinnacle Wealth Management Advisory Group increased its holdings by 2,087 shares, ending with 6,721 shares worth about $7.8 million. Symphony Financial added 1,205 shares, bringing its total to 7,802 shares valued at approximately $9.2 million. Anderson Hoagland boosted its stake by 860 shares, resulting in a total of 23,796 shares worth around $31.1 million.
Eli Lilly and Company Stock Up 0.4%
Eli Lilly's stock closed at $1,279.14 on October 26, 2026, and has recently traded around $1,279.16. The shares are currently above their 50-day moving average by 7.8% and their 200-day moving average by 17.9%. However, the stock is about 3.2% below its 52-week high of $1,321.21.
Recent Earnings
Eli Lilly reported trailing twelve-month revenue of approximately $79.7 billion, with a year-over-year revenue growth of 47.7%. The next earnings report is scheduled for October 29, 2026.
Dividend
Eli Lilly pays an annual dividend of $6.92 per share, yielding about 0.54%. The dividend payout ratio stands at 21.7%.
Insider Buying and Selling at Eli Lilly and Company
Recent insider sales included Anat Hakim, General Counsel, who sold 5,000 shares at an average price of $1,190.00 on August 7, 2026, valued at $5.95 million. Donald A. Zakrowski, an Officer, sold 2,000 shares at an average price of $1,185.01 on August 10, 2026, totaling about $2.37 million. Additionally, Patrik Jonsson, another Officer, sold 6,500 shares at an average price of $1,175.10 on August 17, 2026, valued at approximately $7.6 million.
Analysts Set New Price Targets
On September 28, 2026, JP Morgan maintained an 'Overweight' rating on Eli Lilly with a price target of $1,500. Morgan Stanley also maintained an 'Overweight' rating with a target of $1,430 on October 7, 2026. The consensus recommendation is 'buy', with a mean price target of $1,331.55 based on 30 analyst opinions.
About Eli Lilly
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products globally, including in the United States, Europe, and Asia. The company operates in the healthcare sector, specifically in the drug manufacturing industry, and is headquartered in Indianapolis, Indiana.
Bottom Line
Investors will be watching Eli Lilly's upcoming earnings report on October 29, 2026, for further insights into its financial health. Additionally, First Horizon's reduced stake may reflect its strategy amid recent stock performance and analyst ratings.
Related Filing Alerts
Source: First Horizon's 13F filing on $LLY (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts